-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, WpWw/hB6sAx1zS9mBJOz9gRCyPyqyCoV+usxQfRXEbDO/BJHLdnAuH1xXVzdk8rW wK4b4Ea4Me4bLVnoFzTY2Q== 0001181152-11-000001.txt : 20110104 0001181152-11-000001.hdr.sgml : 20110104 20110104162741 ACCESSION NUMBER: 0001181152-11-000001 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20110103 FILED AS OF DATE: 20110104 DATE AS OF CHANGE: 20110104 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: BONDURANT STUART CENTRAL INDEX KEY: 0001181152 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-27570 FILM NUMBER: 11506194 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: PHARMACEUTICAL PRODUCT DEVELOPMENT INC CENTRAL INDEX KEY: 0001003124 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] IRS NUMBER: 561640186 STATE OF INCORPORATION: NC FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 929 NORTH FRONT STREET CITY: WILMINGTON STATE: NC ZIP: 28401 BUSINESS PHONE: 9102510081 MAIL ADDRESS: STREET 1: 929 NORTH FRONT STREET CITY: WILMINGTON STATE: NC ZIP: 28401 4 1 edgar.xml PRIMARY DOCUMENT X0303 4 2011-01-03 0001003124 PHARMACEUTICAL PRODUCT DEVELOPMENT INC PPDI 0001181152 BONDURANT STUART 205 UNIVERSITY DRIVE CHAPEL HILL NC 27514 1 0 0 0 Common Stock 2011-01-03 4 A 0 2355 0 A 20199 D Stock Options (to buy) 24.52 2010-05-20 2020-05-20 Common Stock 10496 10496 D Stock Options (to buy) 19.19 2009-05-20 2019-05-20 Common Stock 14053 14053 D Stock Options (to buy) 41.32 2008-05-21 2018-05-20 Common Stock 6485 6485 D Stock Options (to buy) 32.67 2007-05-16 2017-05-16 Common Stock 6341 6341 D Stock Options (to buy) 34.18 2006-05-17 2016-05-16 Common Stock 4113 4113 D Stock Options (to buy) 22.98 2005-05-18 2015-05-17 Common Stock 5650 5650 D Exercise price and share amounts reflect an anti-dilution adjustment made in connection with the June 14, 2010 spin-off of Furiex Pharmaceuticals, Inc. Lisa C. Noecker attorney-in-fact for Stuart Bondurant 2011-01-04 -----END PRIVACY-ENHANCED MESSAGE-----